medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2019, Number 3

Next >>

VacciMonitor 2019; 28 (3)

Alum adjuvant tetanus vaccine in simultaneous immunization by mucosal and parenteral routes

Robles-Reyes L, Lastre-González M, Reyes-Díaz LM, Borrego-González Y, Ramos-Pupo R, Vega-García IG, González-Ramírez VE, Rodríguez-Pérez L, Pérez-Martín O

Language: Spanish
References: 24
Page: 85-90
PDF size: 284.29 Kb.


ABSTRACT

Tetanus is caused by Clostridium tetani, a sporulated Gram+ bacterium that produces a potent neurotoxin. Parenteral vaccines produce protective tetanus antitoxin (anti TT) IgG in multiple induction and reactivation doses; vax-TET® is a Cuban parenteral vaccine adsorbed onto alumina. IgAS (secretory), the main mucosal protective antibody, is only induced by the mucous membrane. The oral route, the induction of IgA and its protective role have not been explored. SinTimVaS is applied by simultaneous mucosal and parenteral route that induces systemic IgG similar to the parenteral route and adds an IgA mucosal response. We evaluated the effect of vax-TET® applied in SinTimVaS in Balb/c mice and we explored the influence of adjuvant on the induction of anti-TT IgA. SinTimVaS induced similar serum anti TT IgG responses to two intramuscular doses of vax-TET® but higher than one dose. Three doses of oral vax-TET® did not induce serum anti-TT IgG, whereas adjuvanted with adjuvant Finlay Cocleate 1 (AFCo1) did induce it. It was not possible to determine the IgA anti-TT mucous induction with any of the formulations adjuvanted with alumina; but with the formulation AFCo1 + TT it was induced. We can conclude that vax-TET® in SinTimVaS worked in a similar way to the established parenteral immunization, so it would be possible to reduce the multi-dose vaccination schemes with more potent adjuvant formulations and it is confirmed that powerful adjuvants are required to induce mucosal IgA.


REFERENCES

  1. Schiavo G, Poulain B, Rossetto O, Benfenati F, Tauc L, Montecucco C. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc, EMBO J. 1992;11:3577-83.

  2. Centro Nacional de Epidemiología. Resultados de la vigilancia epidemiológica de las enfermedades transmisibles. Informe anual 2013. Madrid: Centro Nacional de Epidemiología; 2015. Disponible en: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnic. (Consultado en línea: 5 de agosto de 2018).

  3. Gregory DS. Pertussis: A Disease Affecting All Ages. Am Fam Physician 2006;74:420-7.

  4. Rositas-Noriega FH. Tétanos, diagnóstico, tratamiento y prevención. Medicina Universitaria. 2001;10(3):21-32.

  5. López-Ambrón L, Egües-Torres LI, Pérez-Carreras A, Galindo-Santana BM, Galindo-Sardiña MA, Resik-Aguirre S, et al. Experiencia cubana en inmunización, 1962–2016. Rev Panam Salud Pública. 2018;42:e34. https://doi.org/10.26633/RPSP.2018.34.

  6. Wassilak SGF, Roper MH, Murphy TV, Orenstein WA. Tetanus toxoid. En: Plotkin SA, Mortimer EA. Vaccines 4th ed. Philadelphia (PA): Saunders; 2002. p.745-81.

  7. World Health Organization. Tetanus vaccines: WHO Position Paper. Wkly Epidemiol Rec 2017; 92: 53-76. Disponible en: http://apps.who.int/iris/bitstream/10665/254582/1/WER9206.pdf.

  8. Ochoa R. Inmunoepidemiología y Estrategias de Vacunación. La Habana: Finlay Ediciones; 2009.

  9. Pérez-Martín OG, Vega-García IG. Inmunología en el humano sano. La Habana: ECIMED; 2017.

  10. Broder KR, Cortese MM, Iskander JK, Kretsinger K, Slade BA, Brown KH, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-3):1-34.

  11. Pérez-Martín OG, González-Aznar E, Romeu-Alvarez B, del Campo-Alonso JM, Acevedo-Grogues R, Lastre-González M de SJB. et al, inventores. Single-Time Vaccines. World Intellectual Property Organization WO 2010/057447. 2010 May 27.

  12. González E, Romeu B, del Campo J, Acevedo R, Lastre M, Záyas C, et al. Mucosal and systemic immune response against Neisseria meningitidis B induced by single time vaccination strategy. VacciMonitor 2009;18(2):75-7.

  13. González-Aznar E, Romeu B, Lastre M, Zayas C, Cuello M, Cabrera O, et al. Mucosal and systemic immune responses induced by a single time vaccination strategy in mice. Can J Microbiol 2015;61:531-8.

  14. Lastre-González MSJB, Pérez-Fumero Y, Reyes-Díaz LM, Ramírez-González W, Reyes-Zamora MC, Borrego-González Y, et al. Alternatives to multiple doses of allergy´s immunotherapy. En: Frontiers Abstract Book. Immuno Mexico 2018: proceedings of the XII Congress of the Latin American Association of Immunology and XXIII Congress of the Mexican Society of Immunology. Cancún, México, May 14-18, 2018. Lausana, Suiza: Frontiers; 2018:994-7. doi:10.3389/978-2-88945-511-9.

  15. Pérez O, Bracho G, Lastre M, del Campo J, Gil D, Zayas C, et al. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Imm Cell Biol 2004;82:603-10.

  16. Pérez O, Lastre M, Cabrera O, del Campo J, Bracho G, Cuello M, et al. New vaccines require potent adjuvants like AFPL1 and AFCo1. Scand J Immunology 2007;66:271-7.

  17. Romeu B, González E, del Campo J, Acevedo R, Zayas C, Valdez Y, et al. Mucosal and systemic immune response of mice to tetanus toxoid coadministered nasally with AFCo1. Can J Microbiol 2011;57:256-61.

  18. Pérez O, Romeu B, Cabrera O, González E, Batista-Duharte A, Labrada A, et al. Adjuvants are key factors for the development of future vaccines: lessons from the Finlay adjuvant platform. Front Immunol 2013;4:407. doi: 10.3389/Fimmu.2013.00407.

  19. Pérez O, Batista-Duharte A, González E, Zayas C, Balboa J, Cuello M, et al. Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Braz J Med Biol Res 2012;45(8):681-92.

  20. Formulario Nacional de medicamentos [Sitio Web]. La Habana: Ministerio de Salud Pública, c1999. Disponible en: http://fnmedicamentos.sld.cu/index.php (Consultado en línea: 10 de agosto de 2018).

  21. Mónica del Campo J, Ochoa R, Lastre M, Bracho G, Taboada C, Díaz M, Pérez O. ELISA de IgA anti-Lipopolisacárido de Vibrio cholerae en humanos. Vaccimonitor 2002;11(1):5-10.

  22. Ahire VJA, Doshi JBB, Ravetkar SDB, Sawant KKA. Sistema de administración oral del toxoide tetánico. Ars Pharm 2007;48(3):275-96.

  23. Walke S, Srivastava G, Routaray CB, Dhavale D, Pai K, Doshi J, et al. Preparation and characterization of microencapsulated DwPT trivalent vaccine using water soluble chitosan and its in-vitro and in-vivo immunological properties. Int J Biol Macromol 2018;107:2044-56.

  24. Jain S, Harde H, Indulka A, Agarwal A. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration. Nano Med 2014;10:431-40.




2020     |     www.medigraphic.com